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Summary
Memory T cells respond rapidly in part because they are less reliant on a
heightened levels of costimulatory molecules. This enables rapid control
of secondary infecting pathogens but presents challenges to efforts to con-
trol or silence memory CD4 T cells, for example in antigen-specific toler-
ance strategies for autoimmunity. We have examined the transcriptional
and functional consequences of reactivating memory CD4 T cells in the
absence of an adjuvant. We find that memory CD4 T cells generated by
infection or immunisation survive secondary activation with antigen deliv-
ered without adjuvant, regardless of their location in secondary lymphoid
organs or peripheral tissues. These cells were, however, functionally
altered following a tertiary immunisation with antigen and adjuvant, pro-
liferating poorly but maintaining their ability to produce inflammatory
cytokines. Transcriptional and cell cycle analysis of these memory CD4 T
cells suggests they are unable to commit fully to cell division potentially
because of low expression of DNA repair enzymes. In contrast, these
memory CD4 T cells could proliferate following tertiary reactivation by
viral re-infection. These data indicate that antigen-specific tolerogenic
strategies must examine multiple parameters of Tcell function, and pro-
vide insight into the molecular mechanisms that may lead to deletional
tolerance of memory CD4 T cells.
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Introduction
Memory CD4 T cells play central roles in enhancing
immune protection against pathogens the host has previ-
ously encountered.1 However, activated and memory CD4
T cells also contribute to disease processes in chronic
inflammatory conditions, including rheumatoid arthritis
and multiple sclerosis.2–4 Most current treatments for
these conditions require continued use of drugs that
dampen or deplete immune mediators or cells. A cure for
these diseases will require deletion or retraining of the
CD4 T cells that contribute to pathology.
Antigen-specific tolerance strategies have been used for
many years to treat allergies, and there are ongoing trials
in autoimmune patients.5–8 The underlying rationale for
these strategies is based on our knowledge of tolerance
induction in T cells, mainly developed from experiments
examining Tcell receptor (TCR) activation of na€ıve CD4
T cells in the absence of costimulatory and inflammatory
signals.9–11 Much less is known about the consequences
of activating memory CD4 T cells through their TCR
alone. Memory CD4 T cells can respond more quickly to
a secondary challenge. This is, in part, because they are
less reliant on a heightened level of costimulatory sig-
nals,12–14 although memory CD4 T-cell cytokine
responses do require the presence of costimulatory mole-
cules.14,15 While this contributes to rapid pathogen con-
trol, this presents significant hurdles for treatments that
aim to induce antigen-specific tolerance in autoimmunity,
allergy or transplantation.16,17
A deeper understanding of the functional and molecu-
lar consequences of activating memory CD4 T cells with
Abbreviations: BAC, bacterial artificial chromosome; DEG, differently expressed genes; Dox, doxycycline; IAV, influenza A virus;
IFNc, interferon-gamma; IL, interleukin; i.n., intranasal; MedLN, mediastinal lymph node; OVA, ovalbumin; TCR, T-cell recep-
tor; TNF, tumour necrosis factor; TRACE, T-cell reporter of activation and cell enumeration; Treg, regulatory T cell
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TCR signals alone is required to surmount these hurdles.
We recently demonstrated that memory CD4 T cells reac-
tivated with antigen delivered in the absence of adjuvant
return to the memory pool and survive long term.18
However, tertiary reactivation led to a curtailed response.
Here, we address two outstanding questions: 1. whether
the consequences of reactivating memory CD4 T cells
with antigen alone are similar in lymphoid organs and
peripheral tissues and 2. what the underlying cellular
changes responsible for the curtailed tertiary response are.
These are important questions as the pathology for many
autoimmune and allergic conditions is present in periph-
eral tissues, and understanding the mechanisms of mem-
ory CD4 Tcell tolerance is essential to improve treatments
and monitor therapeutic success. Our data show that
while memory CD4 Tcell responses are altered following
exposure to tolerogenic signals, their ability to respond




10-week-old female C57BL/6 mice were purchased from
Envigo (UK). Tcell reporter of activation and cell enu-
meration (TRACE) and C57BL/6 mice were maintained
at the University of Glasgow under specific pathogen-free
conditions in accordance with UK home office regula-
tions (Project Licence P2F28B003) and approved by the
local ethics committee.
To generate mice in which rtTA reports interleukin-2
(IL-2) expression, we used recombineering to extract the
upstream 8.389 kb section of the IL-2 promoter from a
Bacterial Artificial Chromosome (BAC) RP24208L3 (BAC
resource at Children’s Hospital Oakland Research Insti-
tute, Buffalo, New York). This was subcloned into a plas-
mid containing the human CD2 locus control region and
linked to the rtTA sequence. The transgene, cut and puri-
fied from the construct backbone, was used to create
transgenic mice at the Transgenic mouse facility at
National Jewish Health in Jackson Lab C57BL/6 animals.
Two founder pups were identified by PCR, but only one
was fertile. Progeny of this animal were bred with B6.Cg-
Tg(tetO-cre)1Jaw/J (006234) and B6.129X1-Gt(ROSA)
26Sortm1(EYFP+)Cos (006148) both from Jackson Laborato-
ries.
Immunisations and infections
For influenza A virus (IAV) studies, C57BL/6 mice were
briefly anesthetized using inhaled isoflurane and infected
with 200–300 plaque forming units of IAV strain A/
WSN/33 in 20 ll of PBS intranasally (i.n.). IAV was pre-
pared and tittered in MDCK cells. Infected mice were
rechallenged with 100PFU of X31 (kindly provided by
Prof James Stewart, University of Liverpool). Infected
mice were weighed daily. Any animals that lost more than
20% of their starting weight were humanely euthanized.
TRACE mice were given Dox+chow (Envigo) for a total
of 7 days starting 2 days prior to immunisation with
40 µg of ovalbumin (OVA) protein (Worthington) conju-
gated to 20 µm polyethylene carboxylate beads (Poly-
sciences Inc.) with 20 µg of polyinosinic:polycytidinic
acid (InvivoGen) and 20 µg of anti-CD40 (BioXcell) s.c
in the scruff. Recipients of TRACE EYFP+T cells were
given 40 µg of OVA with/out 10 µg lipopolysaccharide
(LPS) i.v. in 100 µl of PBS. NP311–325 was conjugated to
OVA using Imject Maleimide-activated OVA according to
the manufacturer’s instruction (Thermo Fisher). Briefly,
the OVA was reconstituted with 200 µl of Ultrapure
water. 200 µl PBS was added to 2 mg of NP311–325 pep-
tide (JPT) and combined with the OVA and incubated at
room temperature for 2 hours. Excess peptide was
removed by centrifugation using a 30 K centricon filter
(Sigma) for 15 minutes at 3500 g with three washes with
PBS. The conjugate was filter sterilized and the concentra-
tion measured using a Nanodrop (Thermo Fisher). Mice
were immunized with 1 lg NP311–325-OVA delivered i.p
with 0.1 mg alum. For mitosis analysis, C57BL/6 mice
were immunized with 20 lg NP311–325 peptide (JPT) with
10 lg of LPS i.v. After 30 days, they were re-immunized
with 20 lg NP311–325 peptide with/out 10 lg LPS fol-
lowed 30 days later by i.p. immunisation with 5 lg NP-
OVA with 0.1 mg of alum i.p.
FACS sorting and cell transfers
TRACE mice were euthanized 8 days post-immunisation,
and single-cell suspensions were prepared. Lymphoid
organs, including spleen, mediastinal, axillary, brachial
and mesenteric lymph nodes, from individual mice were
pooled and pre-enriched for CD4 T cells using EasySepTM
Mouse T Cell Isolation Kit (Stemcell Technologies). Live,
single, EYFP+ CD4 T cells negative for MHCII, B220,
CD8 and F4/80 were sorted on a BD FACS Aria. Sorted
cells were washed in PBS and 100,000 cells transferred i.v.
into na€ıve C57BL/6 mice.
Tissue preparation
Mice were euthanized either by cervical dislocation or
with a rising concentration of carbon dioxide and per-
fused with PBS-5 mM EDTA in experiments examining
lungs. Spleen and mediastinal lymph nodes (MedLNs)
were processed by mechanical disruption. Single-cell sus-
pensions of lungs were prepared by digestion with 1 mg/
ml collagenase and DNAse (Sigma) for 40 minutes at
37°C. Red blood cells were lysed from the spleen and
lungs using lysis buffer (Thermo Fisher).
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Flow cytometry
A single-cell suspension was stained with PE-labelled IAb/
NP311–325 (NIH tetramer core) at 37°C, 5% CO2 for 2
hours in complete RMPI (RPMI with 10% foetal calf
serum, 100 lg/ml penicillin-streptomycin and 2 mM L-
glutamine) containing Fc block (24G2). Surface antibod-
ies were added, and the cells incubated for a further
20 minutes at 4°C. Antibodies used were as follows: anti-
CD4 BUV805 (BD Biosciences; clone: RM4-5) or CD4
APC-Alexa Fluor 780 (eBioscience; RM4-5), anti-CD44
BUV395 (BD Biosciences; clone: IM7), anti-CXCR5
BV785 (BioLegend; clone:L138D7), anti-PD-1 BV711
(BioLegend: 29F.1A12) and ‘dump’ antibodies: B220
(RA3-6B2), anti-CD8 (53-6.7) and MHC II (M5114) all
on eFluor-450 (eBioscience). Cells were stained with a fix-
able viability dye eFluor 506 (eBioscience). In some cases,
cells were then fixed with FoxP3 Transcription Factor Fix-
ative kit (Thermo Fisher, UK) and stained with anti-
FoxP3 PeCy7 (eBioscience; FJK-16S), anti-Bcl2 FITC
(Biolegend; Blc/10C4) and anti-Ki67 BV605 (Biolegend;
16A8). Phosphorylated H3 was detected in cells fixed with
2%PFA/0.5% saponin using Alexa 647-labelled anti-His-
tone H3 (pS28) (HTA28, Thermo Fisher). Cells were
acquired on a BD LSR or Fortessa and analysed using
FlowJo (version 10 Treestar).
Tcell cytokine analysis
Bone marrow-derived dendritic cells were cultured as
described19 in complete RPMI supplemented with X-63
supernatant for 7 days. A single-cell suspension was incu-
bated with 10 lg/ml NP311–325 peptide for 2 hours prior
to co-culture with lungs, spleen or lymph node cells in
complete RMPI at a ratio of approximately 10 T cells to
1 DC in the presence of Golgi Plug (BD Bioscience). Co-
cultures were incubated at 37°C, 5% CO2 for 6 hours.
Cells were incubated with Fc block and surface stained
with anti-CD4 BUV805 (BD Biosciences; clone: RM4-5)
or CD4 APC-Alexa Fluor 780 (eBioscience; RM4-5), anti-
CD44 BUV395 (BD Biosciences; clone: IM7) and ‘dump’
antibodies: B220 (clone: RA3-6B2), CD8 (53-6.7) and
MHC II (clone: M5114) all on eFluor-450 (eBioscience).
Cells were fixed with cytofix/cytoperm (BD Bioscience)
for 20 minutes at 4°C and stained in perm/wash buffer
with anti-cytokine antibodies for 1 hour at room temper-
ature (anti-IFN-c PE (XMG1.2), anti-TNF Alexa Fluor-
488 (MP6-XT22) anti-IL-2 APC (JES6-5H4) all from
eBioscience.
RNA isolation for RNA-seq
CD4+ EYFP+ cells from the spleen, mediastinal, axillary,
brachial and mesenteric lymph nodes of TRACE cell
recipients were FACS sorted as above, and cell pellets
were stored at 20°C prior to RNA extraction. RNA was
extracted and purified from single-cell suspensions using
RNeasy Micro Kit (Qiagen) according to the manufac-
turer’s instructions.
RNA analysis
Sequencing and library prep were conducted by
LCSciences Ltd. Total RNA was extracted using Trizol
reagent (Invitrogen, CA, USA). Total RNA quantity and
purity were analysed using a Bioanalyzer 2100 and RNA
6000 Nano LabChip Kit (Agilent, CA, USA), and all
samples had RIN numbers >7.0. Approximately 10 µg
of total RNA was subjected to isolate Poly (A) mRNA
with poly-T oligoattached magnetic beads (Invitrogen).
Following purification, the poly(A)- or poly(A)+ RNA
fractions were fragmented using divalent cations under
elevated temperature. The cleaved RNA fragments were
reverse-transcribed to create the final cDNA library in
accordance with the protocol for the mRNA-Seq sample
preparation kit (Illumina, San Diego, USA). The average
insert size for the paired-end libraries was 300 bp
(50 bp). Paired-end sequencing was done on an Illu-
mina Hiseq 4000 (lc-bio, China). Cutadapt software20
was used to remove low-quality reads and adaptor
sequences. High-quality reads were then mapped to a
C57BL/6 mouse reference genome to which the EYFP
sequence was added using HISAT2.21 Readcounts were
obtained from bam files with FeatureCounts using the
default parameters. Differently expressed genes (DEGs)
were obtained with DESeq2, using RStudio (RStudio
Inc). DEGs were visualized with a volcano plot using
the ‘Enhancedvolcano’ package within R. DEGs with a
fold change of at least 3 and q-values less than p = 0.05
were classed as statistically significant. Heatmaps were
generated using the heatmap2 function, using the
DESeq2 normalized counts and Panther22 used to deter-
mine GO biological processes. GSEA analysis was con-
ducted using UC San Diego/Broad Institute’s GSEA
software.23,24
ELISA
Ovalbumin-specific antibody ELISAs were carried out as
described.18 Serum from immunized and control mice
was titrated in 2-fold serial dilution on plates coated with
OVA protein. Anti-mouse IgG, IgG1 or IgG2c biotin
detection antibodies (Thermo Fisher, UK) were used with
Extravidin-peroxidase (Sigma-Aldrich) and SureBlueTMB
substrate (KPL). Absorbance was measured at 450 nm
using a Sunrise Absorbance Reader (Tecan). The absor-
bance of each sample was normalized to a positive con-
trol on each plate after the background absorbance from
a blank well had been removed.
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Statistical analysis
Data were analysed using Prism version 7 software
(GraphPad). Differences between groups were analysed by
unpaired ANOVAs or T-tests as indicated in figure
legends. In all figures, * represents a p value of <0.05;
**p > 0.01, ***p > 0.001 and ****p > 0.0001.
Results
Antigen-specific memory CD4 T cells in lymphoid
organs and in peripheral tissues respond to
tolerogenic signals but fail to increase in number
To investigate the consequence of reactivating memory
CD4 T cells with tolerogenic signals (antigen delivered
without adjuvant), we needed to track antigen-specific
CD4 T cells following secondary and tertiary reactivation.
To achieve this, we generated memory CD4 T cells in
lymphoid organs and peripheral tissues by infecting
C57BL/6 mice with WSN IAV intranasally (i.n.). We used
MHC class II tetramers containing the immunodominant
IAV peptide nucleoprotein (NP)311–325 to identify NP311–
325-specific memory CD4 T cells in the spleen, lung
draining MedLN and lung (Figure S1).
Previously,18 we delivered antigen intravenously (i.v.)
as it is a well-established tolerogenic injection route.18,25–
27 As expected, i.v. injection of NP311–325 and the adju-
vant PolyIC led to an increase of T cells within the spleen
in mice previously infected with IAV. However, there was
no increase in the numbers of antigen-specific CD4 T
cells in the MedLN or lung (Figure S2). These data sug-
gested that the antigen failed to access the MedLN and
lung and that this delivery route could not be used to
address our questions.
In contrast, i.n. instillation of peptide in the presence
(immunogenic) or absence (tolerogenic) of PolyIC led to
reactivation of the memory CD4 T cells in all three
organs (Figure 1A,B with representative FACS plots
shown in Figure S3). Importantly, delivery of peptide in
the absence of adjuvant i.n. to na€ıve animals led to func-
tional tolerance of the antigen-specific CD4 T-cell popu-
lation, validating this injection route for assessment of
memory CD4 Tcell tolerance induction (Figure S4).
We first examined the immediate consequences of reac-
tivating memory CD4 T cells with immunogenic or
tolerogenic signals. Five days following instillation of
NP311–325 peptide delivered with or without PolyIC, anti-
gen-specific CD4 T cells showed evidence of activation
via increased expression of the proliferation marker, Ki67,
in all three organs (Figure 1B,C). Memory CD4 T cells
reactivated in the presence of adjuvant increased in num-
ber as expected (Figure 1D). In contrast, there was no
accumulation of memory CD4 T cells reactivated follow-
ing the tolerogenic instillation of peptide alone. This
suggests that while these cells entered the cell cycle, they
either failed to complete mitosis or rapidly underwent cell
death following proliferation.
Memory CD4 T cells previously exposed to
tolerogenic signals fail to expand upon subsequent
reactivation despite entry into the cell cycle
To examine the longer term consequences of reactivating
memory CD4 T cells with tolerogenic signals, we set up
the experiment displayed in Figure 2A. Thirty days after
infection with IAV, animals were given NP311–325 i.n.
delivered with (immunogenic) or without (tolerogenic)
PolyIC. After a further 30 days, we either examined the
memory cells or performed a tertiary immunisation with
NP311–325 conjugated to ovalbumin (OVA) protein deliv-
ered with the adjuvant alum.
Prior to tertiary reactivation, there were similar num-
bers of memory antigen-specific CD4 T cells in the two
groups in each organ (Figure 2B). The antigen-specific
CD4 T cells reactivated with an immunogenic secondary
injection were able to mount a robust response in all
organs upon tertiary reactivation. In contrast, the CD4 T
cells previously exposed to tolerogenic signals expanded
only slightly in the spleen and not at all in the MedLN
and lung. There was, however, no difference in the
expression of Ki67 in the reactivated CD4 T cells (Fig-
ure 2C).
We also examined the expression of the pro-survival
molecule, Bcl2, to determine whether the memory CD4 T
cells were more prone to apoptosis following tolerogenic
activation (Figure 2D with representative plots in Fig-
ure S5). However, there were no differences in the expres-
sion of Bcl2 between the two groups regardless of
whether we examined the memory or the recalled cells in
any of the three organs. This suggests increased apoptosis
could not account for the poor accumulation of the ter-
tiary reactivated memory CD4 T cells exposed to tolero-
genic signals.
Memory CD4 T cells reactivated with tolerogenic
signals are not converted to regulatory T cells
Previous studies have shown that activation with antigen
alone can lead to tolerance via the induction of FoxP3-ex-
pressing regulatory T cells.28 We found few NP311–325-
specific FoxP3+ cells at any time-point examined (Fig-
ure 3). While there was a slightly increased percentage of
antigen-specific FoxP3+ cells in the mice exposed to
tolerogenic signals at one time-point in the spleen, there
were no differences in the number of FoxP3+ NP311–325-
specific cells between the groups. This suggests that regu-
latory T cell (Treg) conversion does not explain the poor
accumulation of antigen-specific memory CD4 T cells
previously exposed to tolerogenic signals.
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Figure 1. NP311–325-specific memory CD4 T cells reactivated with peptide delivered in the absence of adjuvant respond but fail to accumulate.
C57BL/6 mice were infected with influenza A virus (IAV) on day 30. On day 0, some of these mice were immunized with NP311–325, +/,
PolyIC i.n. IAb/NP311–325 CD44
hi CD4 T cells were examined 5 days later in the spleen, MedLN, and lung (A) and their Ki67 expression (B, C)
or their numbers determined (D). In C and D, each symbol represents one mouse and error bars are SD. In D, the grey dashed line represents
the background staining in na€ıve animals. Data are combined from 3 experiments (3–5 mice/experiment). Cells are gated as shown in Figure S1.
All statistics calculated using a one-way ANOVA with multiple comparisons; ns = not significant, *<0.05, **<0.01, ***<0.001, ****<0.0001.
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Figure 2. NP311–325-specific memory CD4 T cells previously reactivated with peptide without adjuvant fail to accumulate in the lungs after ter-
tiary reactivation. C57BL/6 mice were infected with influenza A virus (IAV) on day 30. On day 0, mice received NP311–325 +/ PolyIC and
some of these mice were immunized i.p with NP-OVA with alum on day 30 (A). The numbers of IAb/NP311–325 CD44
hi CD4 T cells were exam-
ined 5 days later in the spleen, MedLN, and lung (B) and their expression of Ki67 (C) and Bcl2 (D) determined. Each symbol represents one
mouse, and error bars are SD. In B, the grey dashed line represents the background staining in na€ıve animals. Data are combined from 4 experi-
ments (4–8 mice/experiment). All statistics calculated using a one-way ANOVA with multiple comparisons; ns = not significant, *<0.05, **<0.01,
***<0.001, ****<0.0001.
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Memory CD4 T cells exposed to tolerogenic signals
display evidence of mitotic catastrophe following
reactivation
Thus far, our experiments indicated that memory CD4 T
cells activated with tolerogenic signals can survive in the
memory pool but accumulate poorly upon tertiary reacti-
vation. To take an unbiased approach to investigate this
failure, we performed transcriptomics analysis. For this,
we required a significant number of memory CD4 T cells
that could be easily isolated for analysis. As the identifica-
tion of antigen-specific CD4 T cells by MHC tetramers
requires ligation of the TCR by MHC molecules and the
number of epitope-specific cells are limited, we developed
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Figure 3. NP311–325-specific memory CD4 T cells exposed to soluble antigen in the absence of adjuvant are not converted to Tregs. C57BL/6 mice
were infected with influenza A virus on day 30. On day 0, mice received NP311–325 +/ PolyIC i.n. and some of these mice were immunized i.p
with NP-OVA and alum on day 30 (A). The expression of FoxP3 by IAb/NP311–325 CD44
hi CD4 T cells was determined and shown in red and
total CD4 T cells in grey in representative FACS plots (B) and the percentages and numbers of FoxP3 by IAb/NP311–325 CD44
hi CD4 T cells days
0, 5 and 35 shown in (C). The data are from 1 experiment/time-point with 4–5 mice/group/time-point. Each symbol represents the mean of
between 4 and 5 mice, and the error bars are SD, ***<0.001.
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generated a transgenic animal in which the IL-2 promoter
drives the expression of rtTA. These animals were crossed
to B6.Cg-Tg(tetO-cre)1Jaw/J mice and B6.129X1-Gt
(ROSA)26SorTm(EYFP+)Cos mice. In these animals, T
cells activated through the TCR when the animals are
given doxycycline (Dox) become permanently EYFP+
(Figure S6A).
Feeding of the Dox+ diet for 1 week was sufficient to
induce a small population of EYFP+ cells, even in the
absence of immunisation. However, delivery of OVA con-
jugated to 20 lm polyethylene carboxylate beads in com-
bination with the strong adjuvant combination of anti-
CD40 and PolyIC29 drove an increased population of
EYFP+ CD4 T cells above background (Figure S6B,C).
OVA was used for these studies as we required a protein
containing multiple CD4 Tcell epitopes that could be
obtained free of contaminating microbial products, which
would be present in recombinant IAV proteins. More-
over, we found that recombinant nucleoprotein had
intrinsic adjuvant properties.30
To reactivate the memory CD4 T cells, we returned to
systemic i.v. delivery of OVA protein as this is widely
accepted as a consistent tolerogenic route.18,25–27 We
found that secondary immunisation with OVA in the
TRACE mice led to anaphylactic shock, likely a conse-
quence of anti-OVA antibodies. To avoid this, we sorted
EYFP+ CD4 T cells at day 8 after immunisation and
transferred these cells into na€ıve C57BL/6 animals that
were injected with OVA or OVA and LPS i.v. after
22 days and 30 days since the cells were first primed.
Thirty days following this, the recipient animals were
immunised with OVA+ alum and CD4+ EYFP+ cells iso-
lated 5 days later for RNA-seq analysis (Figure 4A).
Gene expression from 5 individual mice in each experi-
mental condition was analysed. One sample from the
tolerogenic group was excluded as the number of EYFP+
CD4 T cells collected was 2.5- to 10-fold higher than any
of the other samples, suggesting an abnormal response or
potential contamination during sorting. Of the DEGs, 898
were expressed at lower levels and 667 at higher levels in
the tolerogenic group compared to the immunogenic
group (Figure 4B). Analysis of Differently Expressed
Genes (DEGs) expressed at higher levels in the tolerised
samples failed to find consistent changes across all four
samples. We, therefore, concentrated on DEGs that were
expressed at lower levels in the tolerised samples. The top
33 DEGs expressed at lower levels that are represented on
the top left of Figure 4B are listed in Table S1. Gene
ontogeny (Panther22) analysis of the biological processes
associated with these DEGs indicated overrepresentation
of gene products involved in ‘DNA-dependent DNA
replication’, ‘spindle organization’ and ‘cell cycle check-
points’ (Table 1 and File S1).
We performed gene set enrichment analysis and found
that the DEGs were enriched for genes within the GO
term, Cell Cycle Checkpoints (Figure 4C); DEGs within
this GO term that were expressed at lower levels in the
tolerogenic samples are displayed as a heatmap (Fig-
ure 4D). A number of these molecules play key roles at
various stages of the cell cycle and in spindle formation
and function. These genes include the essential cyclin,
Cdk131; Aurkb, a key component of the Chromosome
Passenger Complex required for normal spindle assem-
ble32; Mad1l1 (also known as MAD1), a component of
the spindle-assembly checkpoint33,34; and Cdk5rap2,
which plays a number of roles in spindle checkpoints.35,36
Dysfunction of the spindle checkpoint is linked to
death by mitotic catastrophe, a form of cell death that
occurs when cells are unable to complete mitosis.37,38 As
the percentages of CD4 T cells that were Ki67+ after ter-
tiary activation were equivalent regardless of whether or
not they had been activated with immunogenic or tolero-
genic signals (Figure 2C), these data suggest that memory
CD4 T cells activated with tolerogenic signals can enter
the cell cycle but fail to complete cell division following
tertiary reactivation. To investigate this, we examined the
proportion of reactivated memory antigen-specific T cells
in mitosis reasoning that more CD4 T cells would be
found in mitosis in reactivated cells previously exposed to
tolerogenic signals as they would be ‘stuck’ in mitosis.
The percentages of reactivated antigen-specific T cells
in mitosis were determined by the expression of phospho-
rylated (p)Histone 3, present only during mitosis.39 We
focused on cells with increased forward scatter as cells
increase in size during cell division.40 CD4 T cells were
examined 4 days after tertiary reactivation of mice first
immunized with NP311–325 and LPS, then reactivated with
NP311–325 delivered with or without LPS and finally
Figure 4. Transcriptomics and cell cycle analysis indicate that memory CD4 T cells exposed to tolerising signals undergo mitotic catastrophe fol-
lowing further reactivation in vivo. FACS-sorted EYFP+ CD4 T cells from TRACE mice immunized with OVA + anti-CD40 and PolyIC were
transferred into na€ıve C57BL/6 mice that were then immunized with OVA +/ LPS then re-immunized with OVA + alum i.p. 30 days later (A).
EYFP+ CD4 T cells were FACS sorted after a further 5 days and RNA isolated for transcriptomic analysis. The DEGs are displayed in a volcano
plot (B). GESA and heatmap show the expression of DEGs contained within the GO term ‘Cell Cycle Checkpoints’ (GO: 0000075) (C). DEGs
within the GO term and expressed at lower levels in the tolerogenic samples are displayed in a heatmap (D). C57BL/6 mice immunized with
NP311–325 and LPS were injected with NP311–325 +/ LPS 30 days later and finally immunized after a further 30 days with NP-OVA + alum.
5 days later the percentages of forward scatter high IAb/NP311–325 tetramer + cells that expressed phosphorylated Histone3 were examined (E). In
(E), cells are gated as in Figure S1 and plots are concatenated from 4 mice per group. Data are combined from 2 experiment with 4–5 mice/
group, and error bars are SD. Statistical analysis in B calculated by a T-test, **<0.01.
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reactivated with NP-OVA+ alum (Figure 4E). Very few
antigen-specific T cells were positive for p-H3, but consis-
tently more CD4 T cells were p-H3 positive in mice pre-
viously immunised with NP311–325 delivered without, than
with, LPS (Figure 4E). This indicates that the cells in
mice that received tolerogenic signals were more likely to
be mitosis, suggestive of a failure to complete cell divi-
sion.
Mitotic catastrophe often occurs in cells with DNA
damage.41 We, therefore, examined whether any DEGs
were enriched in genes involved in GO term DNA repair.
This was indeed the case (Figure 5A); the DEGs expressed
at lower levels in the tolerised samples are shown as a
heatmap (Figure 5B). The GSEA of the DEGs expressed at
lower levels in the tolerogenic samples indicates that mul-
tiple genes contribute to this enrichment. These data sug-
gest that tolerised memory CD4 T cells display poor repair
of their DNA during reactivation-induced DNA synthesis
and that this is a consequence of reduced expression of a
number of different genes. This, coupled with the low
expression of cell cycle checkpoint proteins, likely com-
promises their ability to commit to cell division.
Memory CD4 T cells exposed to tolerogenic signals
continue to produce cytokine but fail to provide
accelerated help to primary responding B cells
Our data indicate that memory CD4 T cells reactivated
with tolerogenic signals have impaired proliferative
responses. We also wanted to determine whether these
cells were impaired in other ways. To investigate this, we
used the IAV infection model to generate sufficient cells
in multiple organs to examine ex vivo cytokine produc-
tion; cytokine responses are limited in antigen/adjuvant
models.42
Thirty days after mice were infected with IAV, they
were injected with immunogenic or tolerogenic NP311–325
i.n. and then rested for 30 days (Figure 6A). Bone mar-
row dendritic cells loaded with NP311–325 were used to
examine the ex vivo cytokine potential of the memory
CD4 T cells and activated CD4 T cells from mice given a
tertiary immunisation with NP311–325-OVA and alum
delivered i.p. (Figure S7).
The numbers of interferon-gamma- (IFN-c), tumour
necrosis factor- (TNF) or IL-2-producing antigen-specific
memory CD4 T cells were similar in mice exposed to
immunogenic or tolerogenic NP311–325 peptide 35 days
previously (Figure 6B) with no consistent changes found
across the three organs and three cytokines. Five days
after reactivation with NP-OVA+alum, there was an
increase of TNF and IL-2 producing cells in the spleen
and the MedLN in mice previously exposed to NP311–325
and PolyIC. In contrast, there was no increase in the
number of cytokine-producing cells in mice previously
exposed to tolerogenic NP311–325. In neither group did we
see an increase in IFN-c producing CD4 T cells.
Together, these data suggest that, while exposure to
tolerogenic signals affected accumulation of T cells, it did
not prevent their ability to produce cytokines.
To investigate the functional responses of the T cells
further, we examined their ability to provide accelerated
help to primary responding OVA-specific B cells.18,43 We
measured the levels of class-switched, OVA-specific anti-
body 5 days after the tertiary reactivation. As expected,
primary responding mice had very little class-switched,
OVA-specific antibody and IAV-infected mice previously
exposed to immunogenic signals had clearly detectable
levels of OVA-specific immunoglobulin.43 In contrast,
IAV-infected mice that had previously received tolero-
genic signals failed to produce these antibodies at levels
above primary immunised animals, demonstrating an
impaired functional response (Figure 6C).
Memory CD4 T cells exposed to tolerogenic signals
expand following reactivation with influenza virus
Finally, we wanted to test whether the failure of CD4 T
cells exposed to tolerogenic signals to accumulate could
be rescued by reactivation with a more inflammatory
stimulus. We therefore challenged IAV-infected mice
given immunogenic or tolerogenic signals with an hetero-
subtypic form of IAV, X31 (Figure 7A).
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Five days following re-infection, we found significant
increases in the numbers of antigen-specific CD4 T cells
in the lungs and MedLN of mice regardless of their
immunisation history (Figure 7B). This expansion was
less clear in the spleen regardless of previous immunisa-
tion. In all organs, the majority of the antigen-specific
CD4 T cells were Ki67 positive indicating a more robust
response following IAV infection compared to immunisa-
tion (Figure 7C versus Figure 2C).
Discussion
Memory CD4 T cells respond to low doses of antigen
and costimulatory signals, suggesting they will be refrac-
tory to tolerance induction.12–14,44 This presents
significant hurdles for therapies that aim to induce anti-
gen-specific Tcell tolerance.6,17,45
Our previous18 and current data demonstrate that some
but not all functions of memory CD4 T cells are altered
following the exposure of memory CD4 T cells to antigen
delivered in the absence of adjuvant. Our findings
demonstrate that tolerance induction in these cells is both
subtle and complex. This contrasts with investigations of
tolerance induction in na€ıve CD4 T cells that consistently
show silencing of multiple Tcell functions.9–11,46,47
There have been inconsistent reports of whether mem-
ory CD8 T cells undergo tolerance induction following
reactivation with antigen alone. Tolerance induction
appears to be dependent on the specific location of the
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Figure 5. Transcriptomics analysis indicates that memory CD4 T cells exposed to tolerising signal have reduced expression of DNA repair
enzymes. FACS-sorted EYFP+ CD4 T cells from TRACE mice immunized with OVA+anti-CD40 and PolyIC were transferred into na€ıve C57BL/6
mice that were then immunized with OVA +/ LPS then re-immunized with OVA + alum i.p. 30 days later as in Figure 4. EYFP+ CD4 T cells
were isolated by FACS after a further 5 days and RNA isolated for transcriptomic analysis. GSEA shows significant enrichment of the genes
involved within the GO term ‘DNA repair’ (GO: 0006281) (A), and the DEGs expressed at lower levels in the tolerogenic samples are displayed
in a heatmap (B).
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Figure 6. Activation of CD4 T cells with peptide in the absence of adjuvant does not affect CD4 Tcell cytokine production but does prevent them
providing accelerated help to B cells. C57BL/6 mice were infected with influenza A virus (IAV) on day 30. On day 0, mice received NP311–325
+/ PolyIC and some of these mice were immunized i.p with NP-OVA with alum on day 30 (A). On day 35, cells from the spleen, MedLN and
lung were co-cultured with bmDCs loaded with NP311–325 for 6 hours in the presence of Golgi Plug and the number of interferon-gamma- (IFN-
c), tumour necrosis factor- (TNF) and interleukin-2 (IL-2)-producing CD44hi CD4+ T cells examined (B). The levels of IgG, IgG1 and IgG2c
anti-OVA antibodies in the serum were determined on day 5 (C). Each symbol represents one mouse, and error bars are SD. In B, the grey
dashed line represents the background staining in na€ıve animals. Data in B are combined from 2–3 experiments (3–5 mice/experiment). Data in
C are combined from 3 experiments with 4 mice/experiment. All statistics calculated using a one-way ANOVA with multiple comparisons;
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Figure 7. CD4 T cells exposed to peptide in the absence of adjuvant expand following re-infection with influenza A virus (IAV). C57BL/6 mice
were infected with IAV on day 30. On day 0, mice received NP311–325 +/ PolyIC i.n. and some of these mice were infected with 100PFU of
X31 i.n. 30 days after this (A). The numbers of IAb/NP311–325 CD44
hi CD4 T cells were examined 5 days later in the spleen, MedLN, and lung
(B) and their expression of Ki67 determined (C). In B and C, each symbol represents one mouse and error bars are SD. In A, the grey dashed
line represents the background staining in na€ıve animals. Data are combined from 3 experiments (5–6 mice/experiment). All statistics calculated
using a one-way ANOVA with multiple comparisons; ns = not significant, *<0.05, **<0.01, ***<0.001, ****<0.0001.
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lung susceptible to deletion with exogenous antigen, while
those in the central nervous system were resistant.27 In
contrast, memory CD8 T cells essentially ignore and are
therefore unaffected by antigen expressed through an
inducible endogenous system.48 Thus, tolerance induction
in memory CD8 T cells is highly dependent on the
method of tolerogenic stimulation and the location of the
cells.
Consistently in our own and others’ research, memory
CD4 T cells reactivated with antigen alone fail to accu-
mulate following tertiary activation with antigen and
adjuvant.18,49 Our analysis of cell proliferation and sur-
vival signals suggests that this is not a consequence of
reduced entry into the cell cycle nor altered expression of
anti-apoptosis molecules. Instead, our data indicate that
memory CD4 T cells reactivated following exposure to
antigen fail to complete mitosis, a characteristic associated
with the phenomenon of mitotic catastrophe.
Mitotic catastrophe has mainly been studied in tumour
cells treated with ionizing radiation or drugs that cause
DNA damage.41,50–52 Our transcriptomic data indicate
that reactivated memory CD4 T cells previously exposed
to tolerogenic signals have reduced expression of mole-
cules involved in sensing and repairing DNA damage and
in the control of various stages of the cell cycle. Our data
suggest, therefore, a novel form of cell death for memory
CD4 T cells.
In contrast to the poor accumulation of memory CD4
T cells exposed to tolerogenic signals, this did not shut
down cytokine production. We found only small
increases in cytokine-producing CD4 T cells following
reactivation regardless of Tcell activation history. If these
cells are not undergoing cell division, they would not be
at risk of death via mitotic catastrophe. These data sug-
gest that non-cytokine-producing memory CD4 T cells
are more likely to proliferate than those committed to
cytokine production. This agrees with the general con-
cepts within the Tcentral/Teffector memory cell classifica-
tion and with findings from ourselves and others that
cells either making IFN-c, or that are CD62Llo, proliferate
poorly on reactivation.42,53,54
We did find that memory CD4 T cells previously
exposed to tolerogenic signals were unable to provide
accelerated help for primary responding B cells, suggest-
ing cell proliferation may be required for this functional
response. This contrasts with our previous study in which
memory cells exposed to tolerogenic signals could help
primary responding B cells produce class-switched anti-
body.18 There are multiple differences in experimental
procedure between our previous study and the experi-
ments here including the antigen (3 K peptide versus
NP311–325) form of priming (antigen versus infection) and
route of tolerance induction (intravenous versus intrana-
sal) that could explain this difference. Regardless, in our
studies and similar research from others, memory CD4 T
cells reactivated with antigen delivered without adjuvant
accumulate poorly following a subsequent immunisa-
tion.18,49 This suggests that consistently and, regardless of
specificity, priming, memory cell location and route of
injection of tolerogenic signals, memory CD4 T cells reac-
tivated with antigen in the absence of adjuvant proliferate
poorly following reactivation with antigen and adjuvant.
Interestingly, we found that this poor accumulation
could be rescued by re-infection with IAV, a much more
potent challenge to the host than immunisation. These data
suggest that while the responses of memory CD4 T cells
can be moderated by exposure to tolerogenic signals, these
cells may not be permanently silenced. An alternative
explanation is that a portion of the memory CD4 T cells
are not reactivated by antigen immunisations and therefore
remain blind to the tolerogenic signals and free to respond
to the infection. Teasing apart these two possibilities will
require detailed understanding of the micro-location of
memory CD4 T cells within peripheral and lymphoid
organs and which antigen-presenting cells reactivate mem-
ory CD4 T cells following immunisation and infection. A
deeper understanding of these factors will be critical to
address the most effective methods of antigen-specific tol-
erance strategies. Our data, moreover, demonstrate the
importance of analysing multiple phenotypic and func-
tional parameters in trials of antigen-specific therapy.6,45
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